GlobeNewswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:00:00时区推断·⟳ 抓取 04:01:53·⚡ 决策 08-04 04:19:44 +17m51s·84.9 天前
ProMIS Neurosciences将于8月13日发布二季度财报并召开电话会
公告仅说明公司将在2026年8月13日发布二季度财务结果并举行电话会，未披露任何当期业绩、管线数据、融资或监管进展。
📄 原文GlobeNewswire Biotechnology↗ 原文
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NE…
不做 ProMIS Neurosciences（PMN.US）
仅为财报发布日期和电话会安排，尚无业绩、临床或融资实质信息，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 low ↗
消息传播链
- 公司公告将于2026年8月13日16:30 ET召开电话会并发布二季度财报和业务更新。市场反应:PMN.US当日收于14.39美元，日涨4.43%，但该公告只是日程通知。
关键理由
- 公告仅说明公司将在2026年8月13日发布二季度财务结果并举行电话会，未披露任何当期业绩、管线数据、融资或监管进展。
- 临床阶段生物科技公司财报日期通知不改变短期收入、现金流或管线成功概率，无法形成方向性交易。
主要风险
- PMN.US近期波动极高，财报日期通知不应被误读为基本面催化。
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 2,004 字
Company to host investor conference call and webcast at 4:30 p.m. ET.
Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.
The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.
Conference Call and Webcast Information:
| Date: | August 13, 2026 |
| Time: | 4:30 p.m. Eastern Time |
| Dial-in: | 1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International) |
| Conference I.D.: | 13761812 |
| CallMeTM: | Click Here |
| Webcast: | Click Here |
A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
For further information:
Visit us at www.promisneurosciences.com
Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
Investor Relations Contact
Carie Pierce
VP Investor Relations & External Affairs
IR@ProMISNeurosciences.com
Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.
The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.
Conference Call and Webcast Information:
| Date: | August 13, 2026 |
| Time: | 4:30 p.m. Eastern Time |
| Dial-in: | 1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International) |
| Conference I.D.: | 13761812 |
| CallMeTM: | Click Here |
| Webcast: | Click Here |
A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
For further information:
Visit us at www.promisneurosciences.com
Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
Investor Relations Contact
Carie Pierce
VP Investor Relations & External Affairs
IR@ProMISNeurosciences.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。